Author

Alexia F. Kalogeropulou

Observed names: Alexia Kalogeropulou, Kalogeropulou, Alexia

Institution: Foghorn Therapeutics (United States)

Observed institutions: University of Dundee, MRC Protein Phosphorylation and Ubiquitylation Unit, Foghorn Therapeutics (United States), Parkinson's Institute and Clinical Center, Aligning Science Across Parkinson's, Medical Research Council

ORCID: 0000-0001-5185-7694

Observed ORCID: 0000-0001-5185-7694

OpenAlex ID: A5000257912

Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2

2022 · Xingui Liu, Alexia F. Kalogeropulou, et al. · Journal of the American Chemical Society · 203

Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding

2022 · Alexia F. Kalogeropulou, Elena Purlyte, et al. · Biochemical Journal · 136

Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity

2020 · Alexia F. Kalogeropulou, Jordana B. Freemantle, et al. · Biochemical Journal · 69

P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity

2018 · Alexia F. Kalogeropulou, Jing Zhao, et al. · Biochemical Journal · 67

Immunofluorescence-based assay to assess LRRK2 association with microtubules in HEK293 cells v1

2022 · Elena Purlyte, Alexia Kalogeropulou, et al. · 3

Assessment of in vitro kinase activity of over-expressed and endogenous LRRK2 immunoprecipitated from cells v1

2021 · Francesca Tonelli, Alexia Kalogeropulou, et al. · 3

Abstract 5792: Identification of first in class selective ARID1B degraders

2026 · Madeleine Henley, Benjamin Adams, et al. · Cancer Research

Chromatin Remodeling Complexes: Arising Opportunities and Challenges of Targeting Chromatin Remodelers

2024 · Gabriel J. Sandoval, Nathan Gioacchini, et al. · Royal Society of Chemistry eBooks

Works count: 9

Citation count: 481

H-index: 4

I10-index: 4